FDA 483 - Milla Pharmaceuticals, Inc. - March 12, 2026

An FDA inspection of Milla Pharmaceuticals, Inc. in White Bear Lake, MN, revealed a significant deficiency in their post-marketing adverse drug experience procedures. The firm failed to develop and follow written procedures for vendor qualification and auditing, specifically regarding a pharmacovigilance vendor. This indicates a lack of oversight in critical safety reporting processes.